Mr. Floyd is a serial entrepreneur with over 15 years' experience in development of early stage biopharma businesses in infectious diseases, oncology and rare diseases. He founded an early stage enterprise Neurologic, that in-licensed technology from the NIH for a diagnostic test for Alzheimer's disease and was the co-author of the plan that created the Blanchette Rockefeller Neurosciences Institute with the Honorable Jay Rockefeller and Johns Hopkins University. While at Arpida, he served as the CEO for the North American subsidiary of Arpida Ltd and organized the phase 3 program for an MRSA drug and organized the NDA submission. Subsequently, Mr. Floyd led the US efforts to remediate the NDA for Gentium, SpA for defibrotide. Mr. Floyd is the Founder or co-Founder of Bio-AIM, which is developing a monoclonal antibody for Acinetobacter baumannii; Exbaq which is developing therapies for Gram negative pathogens. He is also the co-founder and organizer of Elion Oncology. Mr. Floyd received a BSBA in accounting from Georgetown University and practiced public accounting as a CPA and held various roles of increasing responsibility over the first 15 years of his career in finance and accounting. Since transitioning to Life Sciences, Mr. Floyd has frequently been a Founder, CEO and CFO of these biopharma businesses.